These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12510359)

  • 1. [Pharmacogenetics of disease modifying anti-rheumatic drugs].
    Taniguchi A; Urano W; Tanaka E; Akama H; Yamanaka H; Kamatani N
    Nihon Rinsho; 2002 Dec; 60(12):2339-44. PubMed ID: 12510359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of disease-modifying anti-rheumatic drugs.
    Tanaka E; Taniguchi A; Urano W; Yamanaka H; Kamatani N
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):233-47. PubMed ID: 15121042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
    Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
    Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
    Taniguchi A; Kamatani N
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():686-90. PubMed ID: 15799443
    [No Abstract]   [Full Text] [Related]  

  • 5. The pharmacogenetics of methotrexate.
    Hider SL; Bruce IN; Thomson W
    Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases.
    Mena JP; Salazar-Páramo M; González-López L; Gámez-Nava JI; Sandoval-Ramirez L; Sánchez JD; Figuera LE; Muñoz-Valle FJ; Vazquez del Mercado M; Dávalos IP
    Pharmacogenomics J; 2011 Aug; 11(4):287-91. PubMed ID: 20514079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
    Taniguchi A; Urano W; Tanaka E; Kamatani N
    Nihon Rinsho; 2007 Feb; 65(2):371-9. PubMed ID: 17302286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacogenomics of the immunosuppressive agents].
    Taniguchi A; Urano W; Tanaka E; Kitamura Y; Saito M; Akama H; Yamanak H; Saito T; Kamatani N
    Nihon Rinsho Meneki Gakkai Kaishi; 2002 Feb; 25(1):105-9. PubMed ID: 11963167
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race and methotrexate pharmacogenetics in rheumatoid arthritis.
    Ranganathan P; McLeod H
    J Rheumatol; 2010 May; 37(5):1064; author reply 1065. PubMed ID: 20439524
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.
    Zhang LL; Yang S; Wei W; Zhang XJ
    Pharmacogenet Genomics; 2014 Nov; 24(11):531-8. PubMed ID: 25144752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in the genetic diagnostics of rheumatoid arthritis.
    Nagy ZB; Csanád M; Tóth K; Börzsönyi B; Demendi C; Rigó J; Joó JG
    Expert Rev Mol Diagn; 2010 Jul; 10(5):603-18. PubMed ID: 20629510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside.
    van der Heijden JW; Dijkmans BA; Scheper RJ; Jansen G
    Nat Clin Pract Rheumatol; 2007 Jan; 3(1):26-34. PubMed ID: 17203006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR; Haire CE; Erikson N; Drymalski W; Palmer W; Eckhoff PJ; Garwood V; Maloley P; Klassen LW; Wees S; Klein H; Moore GF
    N Engl J Med; 1996 May; 334(20):1287-91. PubMed ID: 8609945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
    Dervieux T
    J Rheumatol; 2008 Apr; 35(4):550-2. PubMed ID: 18398948
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?
    Stamp L; Roberts R; Kennedy M; Barclay M; O'Donnell J; Chapman P
    Biomed Pharmacother; 2006 Dec; 60(10):678-87. PubMed ID: 17071051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.